Osel Obtains Exclusive License from Danish Research Consortia for IP Related to Osel’s LACTIN-V in Women Undergoing In-Vitro Fertilization

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Osel, Inc. has obtained the exclusive worldwide license to inventions resulting from an investigator-initiated Phase 2 trial of LACTIN-V in IVF.

Click to view original post